1. Home
  2. AHMA vs MGNX Comparison

AHMA vs MGNX Comparison

Compare AHMA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AHMA

Ambitions Enterprise Management Co. L.L.C Class A Ordinary Shares

N/A

Current Price

$1.08

Market Cap

140.6M

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$2.76

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AHMA
MGNX
Founded
2007
2000
Country
United Arab Emirates
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
140.6M
115.8M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
AHMA
MGNX
Price
$1.08
$2.76
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$3.40
AVG Volume (30 Days)
1.9M
1.5M
Earning Date
12-08-2025
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$16.14
P/E Ratio
$180.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.06
$0.99
52 Week High
$39.50
$3.50

Technical Indicators

Market Signals
Indicator
AHMA
MGNX
Relative Strength Index (RSI) 20.75 52.74
Support Level N/A $1.46
Resistance Level $9.75 $3.50
Average True Range (ATR) 0.89 0.24
MACD -0.11 -0.04
Stochastic Oscillator 0.27 3.70

Price Performance

Historical Comparison
AHMA
MGNX

About AHMA Ambitions Enterprise Management Co. L.L.C Class A Ordinary Shares

Ambitions Enterprise Management Co LLC, through its subsidiaries in the UAE, operates as a tour operator, travel agency, and event planning and management services provider. It provides two lines of services, namely, MICE management, a comprehensive coordination and organization of events, and one-stop tourism, a comprehensive travel product that is designed to provide tourists with all the necessary components of a trip in a single and convenient package, which typically include transportation, accommodations, meals, and guided tours or activities.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: